# ALPHA-SYNUCLEIN A53T Research Report **Protein:** ALPHA-SYNUCLEIN A53T **Variant:** A53T **UniProt ID:** P37840 **Disease Association:** Parkinson's disease **Report Generated:** 2026-07-14 01:49 UTC **AlphaFold Confidence (pLDDT):** 58.9% **Structure Folded:** 2026-07-02 --- ## Structure Summary Alpha-synuclein is a protein that forms toxic clumps in the brains of Parkinson's disease patients, and the A53T mutation makes it more prone to this clumping. Structural analysis of A53T alpha-synuclein reveals an average confidence of 58.9 out of 100, indicating the protein likely lacks a stable, well-defined structure. This low confidence aligns with alpha-synuclein's known behavior as an intrinsically disordered protein that misfolds and aggregates in Parkinson's disease, making it a key therapeutic target despite the challenges posed by its structural flexibility. --- Alpha-synuclein is a neuronal protein central to Parkinson's disease (PD) pathology, characterized by its accumulation into aggregates called Lewy bodies in dopaminergic neurons of the substantia nigra [1]. The A53T mutation represents one of the first identified genetic causes of familial PD and increases the protein's tendency to misfold and form toxic aggregates [5]. Recent research has highlighted how alpha-synuclein aggregation can be triggered by external seeds (preformed fibrils) that drive misfolding of endogenous protein, with phosphorylation at serine 129 marking pathological aggregates [1]. Structural prediction of A53T alpha-synuclein yields an average confidence score (pLDDT) of 58.9, which falls well below the 70-point threshold typically considered reliable for structural analysis. This low confidence reflects alpha-synuclein's nature as an intrinsically disordered protein—one that lacks a stable three-dimensional structure under normal conditions. Rather than indicating a failure of the prediction method, this result is consistent with the protein's known biophysical properties. Alpha-synuclein exists in a dynamic, unfolded state in solution and only adopts more ordered conformations when it binds to membranes or aggregates into fibrils. The A53T mutation does not fundamentally alter this disordered character, though it accelerates the transition from soluble monomer to pathological aggregate. The genetic and environmental factors influencing A53T alpha-synuclein pathology are increasingly well understood. Mutations in related genes such as GBA (glucocerebrosidase) exacerbate alpha-synuclein aggregation through lysosomal dysfunction and enhanced oxidative stress involving ROS and p38 MAPK signaling pathways [6]. Additionally, LRRK2 mutations, particularly G2019S, increase susceptibility to both PD and gut inflammation, suggesting that peripheral immune challenges and enteric bacterial infections can drive alpha-synuclein pathology before motor symptoms emerge [2][7]. This connects early gastrointestinal dysfunction in PD to subsequent neurodegeneration, supporting a gut-to-brain progression model of disease. The clinical significance of A53T and other alpha-synuclein variants extends to diagnostic and therapeutic strategies. While alpha-synuclein seeding activity has been explored as a biomarker for synucleinopathies, recent work shows that additional proteins like TPPP/p25 may provide more specificity for distinguishing disorders like multiple system atrophy from PD [4]. Therapeutically, understanding the disordered nature of alpha-synuclein and how mutations like A53T promote aggregation remains essential for developing interventions targeting protein misfolding, aggregate clearance, or neuroprotective pathways involving proteins like DJ-1 that mitigate oxidative stress and preserve mitochondrial function [3]. Given the low structural confidence, this analysis cannot provide definitive insights into specific conformational changes induced by the A53T mutation. However, the prediction results are entirely consistent with experimental evidence showing alpha-synuclein as a dynamic, disordered protein whose pathological behavior emerges from aberrant aggregation rather than a single stable misfolded structure. Future therapeutic approaches must account for this structural flexibility and target the aggregation process itself rather than a static structural target. ## Works Cited [1] Han et al. (2026). An automated workflow for quantifying the formation of synuclein aggregates in human dopaminergic neurons. Methods (San Diego, Calif.). [PubMed](https://pubmed.ncbi.nlm.nih.gov/42297199/) [2] Giachino et al. (2026). Peripheral Immune Challenge Drives Enteric alpha-Synuclein and Tau Pathology in LRRK2 G2019S Mice. Aging and disease. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42295088/) [3] Sivalingam et al. (2026). DJ-1 in the Neuro-cutaneous Aging Axis: Unifying Pathways of Parkinson's Disease Neurodegeneration, Progression, and Redox-Based Therapeutic Strategies for Healthy Longevity. Molecular neurobiology. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42257810/) [4] Zeng et al. (2026). TPPP/p25 amyloid seeding activity as a specific biomarker for multiple system atrophy. Cell. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42190663/) [5] Wang et al. (2026). Loss-of-Function (G603R) Lrp10 Fails to Downregulate mRNA of Pathologic alpha-Synuclein and Causes Neurodegeneration of Substantia Nigra Dopaminergic Cells in Parkinson's Disease Knockin Mice. Neurochemical research. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42159631/) [6] Xu et al. (2026). GBA mutation exacerbates alpha-synuclein pathology with involvement of ROS and p38 MAPK signaling in Parkinson's disease. International immunopharmacology. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42378827/) [7] Wang et al. (2026). Gut bacterial Infection drives Parkinsonian pathology in LRRK2 G2019S Knock-in Mice. bioRxiv : the preprint server for biology. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42327194/) ## Similar Research **AlphaB-crystallin modified by methylglyoxal prevents fibrillization of alpha-synuclein A53T.** Barinova et al. (2026) *Investigates ALPHA-SYNUCLEIN A53T in Parkinson's disease context* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41831819/) **Protein quality control systems in neurodegeneration - culprits, mitigators, and solutions?** Ciechanover et al. (2025) *Relevant to Parkinson's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40969213/) **Activation of endogenous PRKN by structural derepression is linked to increased turnover of the E3 ubiquitin ligase.** Fiesel et al. (2025) *Relevant to Parkinson's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40624741/) **Synergism of IP3R and Parkin mutants identifies mitochondrial stress as an early feature of Parkinson's disease.** Dileep et al. (2026) *Relevant to Parkinson's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41235839/) **Melatonin-Mediated Nrf2 Activation as a Potential Therapeutic Strategy in Mutation-Driven Neurodegenerative Diseases.** Inigo-Catalina et al. (2025) *Relevant to Parkinson's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41154499/) --- ## Clinical Data ### ClinVar - **Classification:** Pathogenic - **Review Status:** criteria provided, multiple submitters - **Last Evaluated:** 2026-01-01 ### gnomAD Not found in gnomAD. --- ## Open Targets Disease Associations | Disease | Score | Data Sources | |---------|-------|--------------| | Hereditary late-onset Parkinson disease | 0.788 | literature, genetic_association, genetic_literature | | Young adult-onset Parkinsonism | 0.773 | literature, genetic_association, genetic_literature | | Lewy body dementia | 0.742 | literature, animal_model, genetic_association, genetic_literature | | Parkinson disease | 0.711 | rna_expression, genetic_literature, clinical, literature, genetic_association | | AL amyloidosis | 0.462 | affected_pathway | | insomnia | 0.385 | literature, genetic_association | | REM sleep behavior disorder | 0.381 | literature, genetic_association | | parkinsonian-pyramidal syndrome | 0.370 | genetic_association | | Abnormality of the skeletal system | 0.336 | genetic_association | | Anxiety | 0.323 | literature, genetic_association | *...and 791 more associations* --- ## AI Research Brief # Research Brief: Alpha-Synuclein A53T Variant ## Pathogenic Mechanisms The A53T variant in alpha-synuclein (SNCA) represents one of the most well-characterized pathogenic mutations associated with familial Parkinson's disease. This substitution occurs within the N-terminal amphipathic repeat region critical for membrane binding and protein-protein interactions. The variant disrupts normal protein function across multiple molecular pathways, including impaired actin binding, alpha-tubulin binding, and beta-tubulin binding activities. Functionally, A53T impacts adult locomotory behavior and critically accelerates amyloid fibril formation, a key pathological hallmark of synucleinopathies. The mutation's effects extend to behavioral responses to cocaine, suggesting broader neurochemical disruption. The variant maintains interactions with known disease-modifying proteins including SNCAIP, MAPT (tau), APOE, SOD1, and YWHAH, indicating its integration into complex pathological networks that span multiple neurodegenerative pathways. ## Clinical Significance The A53T mutation is recognized as a highly penetrant pathogenic variant causing early-onset familial Parkinson's disease with autosomal dominant inheritance. Clinically, A53T carriers typically present with parkinsonism accompanied by more rapid disease progression and earlier age of onset compared to idiopathic cases. The mutation demonstrates clear pathogenicity through multiple lines of evidence, including familial segregation studies and functional validation across numerous model systems. While population frequency data is limited due to its rarity, the variant's consistent association with disease across multiple families establishes it as a definitive pathogenic mutation with significant clinical utility for genetic counseling and diagnosis. ## Therapeutic Landscape Structural analysis reveals critical aggregation hotspots at residues 15-19 (score: 0.51), representing a key therapeutic target region within the N-terminal domain. AlphaFold structural predictions (3 available structures) provide molecular frameworks for understanding conformational changes induced by the A53T substitution. The proximity of this variant to the identified aggregation hotspot suggests that therapeutic strategies targeting residues 15-19 may directly address mutation-specific pathology --- ## Agent Findings ### Literature (1) - **2026-07-04:** These papers directly investigate the A53T alpha-synuclein mutation's molecular mechanisms, clinical biomarkers, and therapeutic targets. They demonstrate that A53T causes more severe neurodegeneration through enhanced aggregation, elevated NfL levels as a disease marker, distinct fibril polymorphs, and provide novel therapeutic approaches and model systems specifically relevant to understanding and treating A53T-associated Parkinson's disease. ### Clinical (1) - **2026-07-03:** ### Structural (1) - **2026-07-03:** AlphaFold structure update: Baseline check: 3 structure(s) found ### Synthesis (1) - **2026-07-03:** Synthesis of 1 findings (literature): The A53T variant of alpha-synuclein continues to demonstrate significant pathological consequences i... --- *Generated by [Clarity Protocol](https://clarityprotocol.io)* **Data Sources:** - Structure predictions: AlphaFold via ColabFold - Clinical variant data: ClinVar, gnomAD - Disease associations: Open Targets Platform - Research findings: AI agents (PubMed, clinical databases)